Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside
Open Access
- 4 December 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7391
Abstract
Ketone bodies are molecules produced from fatty acids in the liver that act as energy carriers to peripheral tissues when glucose levels are low. Carbohydrate- and calorie-restricted diets, known to increase the levels of circulating ketone bodies, have attracted significant attention in recent years due to their potential health benefits in several diseases. Specifically, increasing ketones through dietary modulation has been reported to be beneficial for cardiovascular health and to improve glucose homeostasis and insulin resistance. Interestingly, although excessive production of ketones may lead to life-threatening ketoacidosis in diabetic patients, mounting evidence suggests that modest levels of ketones play adaptive and beneficial roles in pancreatic beta cells, although the exact mechanisms are still unknown. Of note, Sodium-Glucose Transporter 2 (SGLT2) inhibitors have been shown to increase the levels of beta-hydroxybutyrate (BHB), the most abundant ketone circulating in the human body, which may play a pivotal role in mediating some of their protective effects in cardiovascular health and diabetes. This systematic review provides a comprehensive overview of the scientific literature and presents an analysis of the effects of ketone bodies on cardiovascular pathophysiology and pancreatic beta cell function. The evidence from both preclinical and clinical studies indicates that exogenous ketones may have significant beneficial effects on both cardiomyocytes and pancreatic beta cells, making them intriguing candidates for potential cardioprotective therapies and to preserve beta cell function in patients with diabetes.Keywords
Funding Information
- Center for Scientific Review (UL1TR002556, KL2TR002558, 2P30DK020541-45, R01HL 164772, R01HL159062, R01HL146691, R01HL144456, T32HL172255, 24IPA1268813, 23POST1026190, AHA-21POST836407)
- American Heart Association (UL1TR002556, KL2TR002558, 2P30DK020541-45, R01HL 164772, R01HL159062, R01HL146691, R01HL144456, T32HL172255, 24IPA1268813, 23POST1026190, AHA-21POST836407)
- Monique Weill-Caulier and Irma T. Hirschl Trusts (UL1TR002556, KL2TR002558, 2P30DK020541-45, R01HL 164772, R01HL159062, R01HL146691, R01HL144456, T32HL172255, 24IPA1268813, 23POST1026190, AHA-21POST836407)
- Diabetes Action Research and Education Foundation (UL1TR002556, KL2TR002558, 2P30DK020541-45, R01HL 164772, R01HL159062, R01HL146691, R01HL144456, T32HL172255, 24IPA1268813, 23POST1026190, AHA-21POST836407)
This publication has 176 references indexed in Scilit:
- Circulating Beta-Hydroxybutyrate Levels in Advanced Heart Failure with Reduced Ejection Fraction: Determinants and Prognostic ImpactEuropean Journal of Heart Failure, 2024
- Circulating 3-Hydroxy Butyrate Predicts Mortality in Patients with Chronic Heart Failure with Reduced Ejection FractionESC Heart Failure, 2024
- Downregulation of HDAC9 by the ketone metabolite β‐hydroxybutyrate suppresses vascular calcificationThe Journal of Pathology, 2022
- Exogenous d‐β‐hydroxybutyrate lowers blood glucose in part by decreasing the availability of L‐alanine for gluconeogenesisEndocrinology, Diabetes & Metabolism, 2021
- Chronic Exogenous Ketone Supplementation Blunts the Decline of Cardiac Function in the Failing HeartESC Heart Failure, 2021
- Nuclear Magnetic Resonance-Based Metabolomics Identifies Phenylalanine as a Novel Predictor of Incident Heart Failure Hospitalisation: Results from PROSPER and FINRISK 1997European Journal of Heart Failure, 2017
- Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled TrialEuropean Journal of Heart Failure, 2016
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbitsDiabetologia, 2016
- Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without DiabetesJAMA, 2014
- Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetenceDiabetologia, 1995